In terms of the PSC function, CTHRC1 treatment markedly increased the genetic expression of tumor-promoting growth factors (EGF, HGF, and FGF by 4.9, 4.4, and 10.5 times, respectively) and cytokines (IL8 and IL10 by 3.7 and 2.9 times, respectively) (Figure 4D). The gene discussed is EGF; the disease is neoplasm.